{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:06:46Z","timestamp":1790482006195,"version":"4.1.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1136\/ijgc-2022-003806","type":"journal-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T10:51:06Z","timestamp":1665658266000},"page":"1455-1462","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Primary mucinous ovarian cancer: options for surgery and chemotherapy"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3205-0128","authenticated-orcid":false,"given":"Katherine C","family":"Kurnit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0810-2648","authenticated-orcid":false,"given":"Michael","family":"Frumovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2022-003806_bb0010","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/01.pgp.0000101080.35393.16","article-title":"The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin","volume":"23","author":"Seidman","year":"2004","journal-title":"Int J Gynecol Pathol"},{"key":"10.1136\/ijgc-2022-003806_bb0015","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1097\/00000478-200307000-00014","article-title":"Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis","volume":"27","author":"Seidman","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"10.1136\/ijgc-2022-003806_bb0020","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ygyno.2019.05.009","article-title":"Adjuvant chemotherapy is not associated with a survival benefit for patients with early stage mucinous ovarian carcinoma","volume":"154","author":"Nasioudis","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-003806_bb0025","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1200\/JCO.2004.08.078","article-title":"Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment","volume":"22","author":"Hess","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-003806_bb0030","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2006.10.2517","article-title":"Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group study","volume":"25","author":"Winter","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-003806_bb0035","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.ygyno.2019.03.256","article-title":"An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC\/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor","volume":"153","author":"Gore","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-003806_bb0040","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/cncr.25460","article-title":"Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a Gynecologic Oncology Group study","volume":"117","author":"Zaino","year":"2011","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2022-003806_bb0045","doi-asserted-by":"crossref","DOI":"10.1186\/s13000-021-01079-2","article-title":"Primary mucinous ovarian tumors vs. ovarian metastases from gastrointestinal tract, pancreas and biliary tree: a review of current problematics","volume":"16","author":"Dundr","year":"2021","journal-title":"Diagn Pathol"},{"key":"10.1136\/ijgc-2022-003806_bb0050","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-8-252","article-title":"Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study","volume":"8","author":"Pignata","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1136\/ijgc-2022-003806_bb0055","first-page":"3501","article-title":"Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study","volume":"25","author":"Pisano","year":"2005","journal-title":"Anticancer Res"},{"key":"10.1136\/ijgc-2022-003806_bb0060","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1136\/jcp.2010.085688","article-title":"Immunohistochemistry in the distinction between primary and metastatic ovarian mucinous neoplasms","volume":"65","author":"McCluggage","year":"2012","journal-title":"J Clin Pathol"},{"key":"10.1136\/ijgc-2022-003806_bb0065","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.critrevonc.2016.03.015","article-title":"Mucinous ovarian cancer: a therapeutic review","volume":"102","author":"Xu","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1136\/ijgc-2022-003806_bb0070","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/jcp.2009.072355","article-title":"Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype","volume":"63","author":"Kelly","year":"2010","journal-title":"J Clin Pathol"},{"key":"10.1136\/ijgc-2022-003806_bb0075","article-title":"Combination of cancer antigen 125 and carcinoembryonic antigen can improve ovarian cancer diagnosis","volume":"58","author":"S\u00f8rensen","year":"2011","journal-title":"Dan Med Bull"},{"key":"10.1136\/ijgc-2022-003806_bb0080","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJMra1813254","article-title":"Mucinous ovarian carcinoma","volume":"380","author":"Morice","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-003806_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics10010052","article-title":"Mucinous cancer of the ovary: overview and current status","volume":"10","author":"Babaier","year":"2020","journal-title":"Diagnostics"},{"key":"10.1136\/ijgc-2022-003806_bb0090","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.gore.2017.08.006","article-title":"Staging surgery in early-stage ovarian mucinous tumors according to expansile and infiltrative types","volume":"22","author":"Gouy","year":"2017","journal-title":"Gynecol Oncol Rep"},{"key":"10.1136\/ijgc-2022-003806_bb0095","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/AOG.0b013e3181e7961d","article-title":"Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary","volume":"116","author":"Schmeler","year":"2010","journal-title":"Obstet Gynecol"},{"key":"10.1136\/ijgc-2022-003806_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijsu.2017.03.023","article-title":"Is lymphadenectomy necessary in mucinous ovarian cancer? A single institution experience","volume":"41","author":"Salgado-Ceballos","year":"2017","journal-title":"Int J Surg"},{"key":"10.1136\/ijgc-2022-003806_bb0105","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/1471-0528.14425","article-title":"Incidence of lymph node metastases in clinical early-stage mucinous and seromucinous ovarian carcinoma: a retrospective cohort study","volume":"124","author":"van Baal","year":"2017","journal-title":"BJOG"},{"key":"10.1136\/ijgc-2022-003806_bb0110","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/1471-0528.14226","article-title":"Surgical lymph node assessment in mucinous ovarian carcinoma staging: a systematic review and meta-analysis","volume":"124","author":"Hoogendam","year":"2017","journal-title":"BJOG"},{"key":"10.1136\/ijgc-2022-003806_bb0115","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.ejca.2012.12.004","article-title":"Primary invasive mucinous ovarian carcinoma of the intestinal type: importance of the expansile versus infiltrative type in predicting recurrence and lymph node metastases","volume":"49","author":"Muyldermans","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2022-003806_bb0120","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2019.30.e95","article-title":"Accuracy of frozen section diagnosis and factors associated with final pathological diagnosis upgrade of mucinous ovarian tumors","volume":"30","author":"Park","year":"2019","journal-title":"J Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-003806_bb0125","doi-asserted-by":"crossref","first-page":"46 e1","DOI":"10.1016\/j.ajog.2012.10.863","article-title":"The role of appendectomy for mucinous ovarian neoplasms","volume":"208","author":"Lin","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"10.1136\/ijgc-2022-003806_bb0130","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ijsu.2015.04.043","article-title":"Should we remove the normal-looking appendix during operations for borderline mucinous ovarian neoplasms? A retrospective study of 129 cases","volume":"18","author":"Ozcan","year":"2015","journal-title":"Int J Surg"},{"key":"10.1136\/ijgc-2022-003806_bb0135","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ygyno.2016.10.041","article-title":"Is it necessary to perform routine appendectomy for mucinous ovarian neoplasms? A retrospective study and meta-analysis","volume":"144","author":"Cheng","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-003806_bb0140","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/jnci\/djy071","article-title":"Invasive epithelial ovarian cancer survival by histotype and disease stage","volume":"111","author":"Peres","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/ijgc-2022-003806_bb0145","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/IGC.0000000000001263","article-title":"International study of primary mucinous ovarian carcinomas managed at tertiary medical centers","volume":"28","author":"Mueller","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2022-003806_bb0150","doi-asserted-by":"crossref","first-page":"290","DOI":"10.4143\/crt.2014.004","article-title":"Safety of fertility-sparing surgery in primary mucinous carcinoma of the ovary","volume":"47","author":"Lee","year":"2015","journal-title":"Cancer Res Treat"},{"key":"10.1136\/ijgc-2022-003806_bb0155","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1634\/theoncologist.2017-0310","article-title":"Results of fertility-sparing surgery for expansile and infiltrative mucinous ovarian cancers","volume":"23","author":"Gouy","year":"2018","journal-title":"Oncologist"},{"key":"10.1136\/ijgc-2022-003806_bb0160","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.gore.2017.09.011","article-title":"Is uterine preservation combined with bilateral salpingo-oophorectomy to promote subsequent fertility safe in infiltrative mucinous ovarian cancer?","volume":"22","author":"Gouy","year":"2017","journal-title":"Gynecol Oncol Rep"},{"key":"10.1136\/ijgc-2022-003806_bb0165","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(21)00006-1","article-title":"Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Shi","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2022-003806_bb0170","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","article-title":"Randomized trial of cytoreductive surgery for relapsed ovarian cancer","volume":"385","author":"Harter","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-003806_bb0175","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","article-title":"Secondary surgical cytoreduction for recurrent ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-003806_bb0180","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-003806_bb0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-003806_bb0190","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2000.18.1.106","article-title":"Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study","volume":"18","author":"Muggia","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-003806_bb0195","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1200\/JCO.2000.18.17.3084","article-title":"Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer","volume":"18","author":"Neijt","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-003806_bb0200","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(02)09738-6","article-title":"Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial","volume":"360","author":"International Collaborative Ovarian Neoplasm Group","year":"2002","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2022-003806_bb0205","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2004.12.056","article-title":"Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience","volume":"97","author":"Pectasides","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-003806_bb0210","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1349-7006.2008.01065.x","article-title":"Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: a potential treatment strategy","volume":"100","author":"Sato","year":"2009","journal-title":"Cancer Sci"},{"key":"10.1136\/ijgc-2022-003806_bb0215","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2018-000150","article-title":"A descriptive report of outcomes of primary mucinous ovarian cancer patients receiving either an adjuvant gynecologic or gastrointestinal chemotherapy regimen","author":"Schlappe","year":"2019","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2022-003806_bb0220","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1097\/AOG.0000000000003579","article-title":"Effects of gastrointestinal-type chemotherapy in women with ovarian mucinous carcinoma","volume":"134","author":"Kurnit","year":"2019","journal-title":"Obstet Gynecol"},{"key":"10.1136\/ijgc-2022-003806_bb0225","author":"National Comprehensive Cancer Network","year":"2022","journal-title":"Ovarian cancer including fallopian tube cancer and primary peritoneal cancer (version 1.2022)"},{"key":"10.1136\/ijgc-2022-003806_bb0230","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s00404-020-05489-3","article-title":"Advanced stage primary mucinous ovarian carcinoma. Where do we stand ?","volume":"301","author":"Nasioudis","year":"2020","journal-title":"Arch Gynecol Obstet"},{"key":"10.1136\/ijgc-2022-003806_bb0235","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease\u2020","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2022-003806_bb0240","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ygyno.2020.07.011","article-title":"Long term survival outcomes of stage I mucinous ovarian cancer - a clinical calculator predictive of chemotherapy benefit","volume":"159","author":"Richardson","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-003806_bb0245","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2022-003806_bb0250","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-003806_bb0255","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1136\/ijgc-2020-001640","article-title":"Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-)","volume":"30","author":"Fagotti","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2022-003806_bb0260","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-003806_bb0265","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.21.00605","article-title":"Secondary cytoreduction and carboplatin hyperthermic intraperitoneal chemotherapy for platinum-sensitive recurrent ovarian cancer: an MSK team ovary phase II study","volume":"39","author":"Zivanovic","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-003806_bb0270","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00404-020-05636-w","article-title":"Is there a promising role of HIPEC in patients with advanced mucinous ovarian cancer?","volume":"303","author":"Iavazzo","year":"2021","journal-title":"Arch Gynecol Obstet"},{"key":"10.1136\/ijgc-2022-003806_bb0275","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1245\/s10434-018-6464-z","article-title":"Peritoneal carcinomatosis of rare ovarian origin treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a multi-institutional cohort from PSOGI and BIG-RENAPE","volume":"25","author":"Mercier","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1136\/ijgc-2022-003806_bb0280","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1200\/JCO.2011.39.7166","article-title":"Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"30","author":"Chua","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-003806_bb0285","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.641053","article-title":"Clinicopathological characteristics and prognostic prediction in pseudomyxoma peritonei originating from mucinous ovarian cancer","volume":"11","author":"Fu","year":"2021","journal-title":"Front Oncol"},{"key":"10.1136\/ijgc-2022-003806_bb0290","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Qu\u00e9net","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2022-003806_bb0295","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/jog.13496","article-title":"Long-term survival with bevacizumab in heavily pretreated and platinum-resistant mucinous ovarian cancer: a case report","volume":"44","author":"Tarumi","year":"2018","journal-title":"J Obstet Gynaecol Res"},{"key":"10.1136\/ijgc-2022-003806_bb0300","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.ygyno.2009.10.068","article-title":"A case of progressive mucinous ovarian cancer of low malignant potential responsive to biologic therapy with bevacizumab","volume":"116","author":"Winer","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-003806_bb0305","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ygyno.2018.05.008","article-title":"Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses","volume":"150","author":"Mueller","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-003806_bb0310","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-015-1421-8","article-title":"Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms","volume":"15","author":"Mackenzie","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1136\/ijgc-2022-003806_bb0315","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-11862-x","article-title":"The molecular origin and taxonomy of mucinous ovarian carcinoma","volume":"10","author":"Cheasley","year":"2019","journal-title":"Nat Commun"},{"key":"10.1136\/ijgc-2022-003806_bb0320","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/path.4088","article-title":"Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas","volume":"229","author":"Anglesio","year":"2013","journal-title":"J Pathol"},{"key":"10.1136\/ijgc-2022-003806_bb0325","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-015-0210-y","article-title":"Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors","volume":"7","author":"Ryland","year":"2015","journal-title":"Genome Med"},{"key":"10.1136\/ijgc-2022-003806_bb0330","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061565","article-title":"HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer","volume":"8","author":"Chay","year":"2013","journal-title":"PLoS One"},{"key":"10.1136\/ijgc-2022-003806_bb0335","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-9-433","article-title":"HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy","volume":"9","author":"McAlpine","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1136\/ijgc-2022-003806_bb0340","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ygyno.2019.12.015","article-title":"Therapeutic options for mucinous ovarian carcinoma","volume":"156","author":"Gorringe","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-003806_bb0345","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-003806_bb0350","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2022-003806_bb0355","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"key":"10.1136\/ijgc-2022-003806_bb0360","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-003806_bb0365","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2A, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2022-003806_bb0370","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2022-003806_bb0375","first-page":"125","article-title":"Clinical significance of hormonal receptor status of malignant ovarian tumors","volume":"36","author":"Tkalia","year":"2014","journal-title":"Exp Oncol"},{"key":"10.1136\/ijgc-2022-003806_bb0380","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.6004\/jnccn.2012.0113","article-title":"Metastatic mucinous ovarian cancer and treatment decisions based on histology and molecular markers rather than the primary location","volume":"10","author":"Jain","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1136\/ijgc-2022-003806_bb0385","doi-asserted-by":"crossref","first-page":"6532","DOI":"10.1158\/1078-0432.CCR-13-1305","article-title":"Targeting SRC and tubulin in mucinous ovarian carcinoma","volume":"19","author":"Liu","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2022-003806_bb0390","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1158\/1078-0432.CCR-10-3176","article-title":"Targeting SRC in mucinous ovarian carcinoma","volume":"17","author":"Matsuo","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2022-003806_bb0395","first-page":"215","article-title":"Potential signaling pathways as therapeutic targets for overcoming chemoresistance in mucinous ovarian cancer","volume":"8","author":"Niiro","year":"2018","journal-title":"Biomed Rep"},{"key":"10.1136\/ijgc-2022-003806_bb0400","first-page":"572","article-title":"Establishment of patient-derived tumor xenograft models of mucinous ovarian cancer","volume":"10","author":"Ricci","year":"2020","journal-title":"Am J Cancer Res"},{"key":"10.1136\/ijgc-2022-003806_bb0405","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1158\/1535-7163.MCT-17-1050","article-title":"PRKRA\/PACT expression promotes chemoresistance of mucinous ovarian cancer","volume":"18","author":"Hisamatsu","year":"2019","journal-title":"Mol Cancer Ther"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24007242?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24007242?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2022-003806","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T12:39:26Z","timestamp":1753101566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24007242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":80,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1048891X24007242"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2022-003806","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary mucinous ovarian cancer: options for surgery and chemotherapy","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2022-003806","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 IGCS and ESGO 2022. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}